Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01889 (ankylosing spondylitis)
 5,717 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In patients with established ankylosing spondylitis (AS) and a healthy control group, plasma levels of IGF-1 and TNF-alpha as well as possible connections with biochemical markers of the bone metabolism, humoral inflammatory activity (ESR, CRP), clinical manifestations, and an established clinical activity score (Bath Ankylosing Spondylitis Activity Index = BASDAI) were examined. In AS-patients (men and women) significantly increased TNF-alpha levels were found. Moreover, patients with enthesopathy showed a significantly more frequent increase of CRP and TNF-alpha levels besides an increased urinary pyridinium cross-link excretion. In addition, a significant positive correlation between TNF-alpha, CRP, BASDAI, and urinary pyridinium cross-link excretion was proved, besides a significant negative correlation of IGF-I to urinary pyridinium cross-links and TNF-alpha levels. Summing up, it may be said that TNF-alpha seems to be a reliable surrogate marker in enthesitis. This was proved so far for IgA and endothelium stimulating angiogenic factor only. Besides, the present results argue against a stimulation of osteogenesis. The catabolic situation under high TNF-alpha and low IGF-1 levels may play an important role in the pathogenesis of osteoporosis in AS.
 ...
PMID:Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. 1114 93

Vertebral fractures due to osteoporosis are a common but frequently unrecognized complication of ankylosing spondylitis (AS) and various factors may contribute to the development of osteoporosis in AS. It is known that inflammatory activity in rheumatic disease (i.e., proinflammatory cytokines) itself plays a possible role in the pathophysiology of bone loss. 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) seems to be another possible candidate for mediatory function in regulating both the inflammatory process and bone turnover. The aim of this study was to evaluate the relation between disease activity, bone turnover and calciotropic hormones. In 70 patients with established AS and an age- and sex-matched control group, the relation between disease activity (erythrocyte sedimentation rate, C-reactive protein, Bath Ankylosing Spondylitis Disease Activity Index), and serum levels of vitamin D metabolites, parathyroid hormone (PTH), bone alkaline phosphatase (bAP) and urinary pyridinium cross-links were determined. Serum levels of 1,25(OH)2D3 (p<0.01) and PTH (p<0.01) were negatively correlated with disease activity, the excretion of urinary pyridinium crosslinks showed a positive correlation with disease activity (p<0.01), and 1,25(OH)2D3 and PTH were positively correlated with bAP (p<0.01). These results indicate that high disease activity in AS is associated with an alteration in vitamin D metabolism and increased bone resorption. Furthermore, the decreased levels of 1,25(OH)2D3 may contribute to a negative calcium balance and inhibition of bone formation. Our results suggest further research is necessary to determine whether low levels of 1,25(OH)2D3 as an endogenous immune modulator suppressing activated T cells and cell proliferation may accelerate the inflammation process in AS.
 ...
PMID:Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. 1184 29

The increased prevalence of osteoporosis and recognition of the importance of subchondral bone marrow inflammation in ankylosing spondylitis, together with in vitro and animal model data indicating that bisphosphonates may possess anti-inflammatory properties, constitute a theoretical rationale for their evaluation in this disease. Open evaluation of intravenous pamidronate in some but not all studies has demonstrated efficacy whilst controlled evaluation of a monthly regime has shown that therapy is efficacious in about 60% of patients, although effects are delayed, treatment being necessary for at least 6 months.
 ...
PMID:Bisphosphonates--targeting bone in the treatment of spondyloarthritis. 1246 70

In the course of 2002, several new studies were published confirming the efficacy of bisphosphonate drugs in fracture prevention in patients with osteoporosis. Further evidence was provided of their long duration of action, making intermittent administration possible. The potent bisphosphonate zoledronate can be given at intervals of as long as 1 year and produces changes in bone density and in markers of bone turnover comparable with those seen with conventional daily oral dosing with alendronate or risedronate. If such regimens are proven to prevent fractures, their convenience is likely to result in their widespread adoption and potentially an increase in compliance with these medications. Further evidence has been presented documenting the value of bisphosphonates in preventing the skeletal complications of malignancy, and possibly in reducing mortality in patients with breast cancer. The role of bisphosphonates in osteogenesis imperfecta was further confirmed, and novel roles in ankylosing spondylitis, myelofibrosis, and hypertrophic pulmonary osteoarthropathy were suggested.
 ...
PMID:Bisphosphonates: new indications and methods of administration. 1281 75

To compare the bone mineral density (BMD) and determine the frequency of osteoporosis in mild and advanced ankylosing spondylitis (AS) cases. Seventy three patients with AS were enrolled in this study. The BMD was analyzed at the lumbar spine and hip by dual energy X-ray absorptiometry. The patients were diagnosed as being "normal, osteopenia, or osteoporosis" according to the WHO classification. Using the BASRI-lumbar and BASRI-hip scores, the patients were grouped in mild and advanced AS categories. The mean BMD in the lumbar spine and hip of patients with mild and advanced AS was similar (p > 0.05). While 61.6% of the patients were found to have osteopenia or osteoporosis in the lumbar spine, 46.6% had osteopenia or osteoporosis in the total hip. Of the patients with advanced AS 54.3% had osteopenia or osteoporosis in the lumbar spine, 75% in the total hip. Of the patients with mild AS patients had 68.4% osteopenia or osteoporosis in the lumbar spine, and 42.3% in the total hip. The osteopenia or osteoporosis frequency of the mild and advanced cases of AS in the lumbar spine was similar (p > 0.05). In the advanced AS patients, osteopenia or osteoporosis frequency was significantly higher in the total hip than in the mild AS patients (p < 0.05). In conclusion, there was evidence of osteoporosis in both the advanced AS and mild AS patients. The reason why the anteroposterior lumbar DXA results in the advanced AS patients were similar to the mild ones may be due to the existence of syndesmophytes and ligament calcification. In these cases, it is more convenient to use a hip DXA for assessing the extent of osteoporosis.
 ...
PMID:Bone mineral density in mild and advanced ankylosing spondylitis. 1283 74

A clinical evaluation of phenylbutazone and Butapyrin(R) (a mixture of phenylbutazone and aminopyrine) was made in 409 patients who had a variety of rheumatic diseases. Preliminary European claims were substantiated.In gout a specific favorable effect was brought about by phenylbutazone alone. Effects equivalent to the previously reported favorable response to Butapyrin (Irgapyrin) were observed when its constituent phenylbutazone was used alone. The drug had a suppressive effect in a high percentage of patients with rheumatoid arthritis, ankylosing spondylitis, arthritis with psoriasis and mixed arthritis (rheumatoid arthritis plus osteoarthritis). Favorable effect in peritendinitis of the shoulders, osteoporosis of the spine and acute lumbosacral strain also was noted. Toxicity resulted in discontinuance of medication in 10 per cent of patients with each drug. Manifestations of toxicity generally included fluid retention, nausea and rash, but there were several instances of transitory leukopenia and anemia. There was one instance of agranulocytosis with Butapyrin but none with phenylbutazone.dagger Aggravation of peptic ulcer occurred in ten patients with hemorrhage in two. Generally the toxicity was of a low order as compared with that of other drugs having an antirheumatic effect.
 ...
PMID:Phenylbutazone (butazolidin) and butapyrin; a study of clinical effects in arthritis and gout. 1300 82

The aim of this study was to determine bone mineral density (BMD) of the forearm and of the femoral neck using DXA technique and evaluation of broadband ultrasound attenuation (BUA) and speed of sound (SOS) of the heel using QUS technique in patients with ankylosing spondylitis (AS). The group of 59 AS patients were involved in the study: 53 male and 6 female with average age (40.0 +/- 8.2 yrs), range 29 to 49. Average disease duration was 160.6 +/- 98.0 months, range 18 to 420 months. AS patients were compared to 60 healthy controls: 50 male and 10 non post-menopausal female (average age 38.2 +/- 7.4 yrs). FA-BMD (distal radius) was evaluated using DTX-200 (Osteometer Medi-Tech A/S Denmark) and FN-BMD using ECLIPSE (Norland Medical Systems, Inc., Fort Atkinson, WI). QUS parameters of the left heel (BUA and SOS) were measured by DTU-ONE (Osteometer Medi-Tech A/S Denmark). AS patients are related only to low bone mass of femoral neck (0.786 g/cm2 vs 0.901 g/cm2, p < 0.001). This group relative young patients with chronic inflammatory process is in the increased risk group of hip fracture. QUS measurements of the heel and DXA of forearm do not appear to be a good predictor for screening of AS pts with osteoporosis.
 ...
PMID:[Osteoporosis in ankylosing spondylitis: comparison of dual-energy X-ray absorptiometry (DXA) and quantitative ultrasonography (QUS)]. 1506 33

Cervical spine fractures in patients with ankylosing spondylitis are serious and potentially lethal injuries with high complication rates. Treatment obstacles include long lever arms that generate large forces on any fixation device, osteoporosis, and, usually, kyphotic deformity. The Olerud Cervical Fixation System (OC), with cervical pedicle screws and rods, offers an opportunity to create a biomechanically stable posterior fixation in these complicated cases. The present study is a retrospective chart review and a radiological follow-up of patients with this diagnosis, treated at our department between 1995 and 2000. Nineteen patients (two women) with a mean age of 60 years (32-78 years) were included. The fracture levels were predominantly C5-C6 (five patients) and C6-C7 (five patients). All patients were treated with a long posterior fixation with the OC, and in four patients this was combined with an anterior plate fixation. One patient with severe lordosis also received a short posterior plate fixation. The patients' notes and plain radiographs have been reviewed. Five patients died during the post-operative follow-up period; the others had a mean follow-up time of 24 months (10-55 months). Eleven patients had no neurological deficits preoperatively. One of them developed moderate weakness in his right arm, postoperatively, due to a misplaced pedicle screw in the right pedicle of C5. However, after extraction of the screw he almost totally recovered in 6 months. Eight patients had neurological deficits. Two were paraplegic; two had motor weakness combined with sensory deficiency, and four had a sensory deficiency. Two of the patients with neurological deficits improved postoperatively, but the others were unchanged. Peroperative problems were recorded in five patients; one C6 pedicle was perforated, and two patients had pedicles on one or more levels that the surgeon was not able to probe. In one of the latter patients, transfacet screws were chosen, instead, for one of the levels. Extensive peroperative bleeding was encountered in two patients. One deep-wound infection was noted, postoperatively, and required surgical drainage, but no patients have been re-operated due to loosening of the instrument or to healing problems. In conclusion, the results of the present study indicate that the OC--and possibly other similar long-fixation systems that allow using both pedicle screws and lateral mass screws rigidly connected to a rod--is suited for treating subaxial cervical spine fractures in patients with ankylosing spondylitis, allowing high healing rates.
 ...
PMID:Posterior fixation of subaxial cervical spine fractures in patients with ankylosing spondylitis. 1514 95

The therapeutic specialties of osteoporosis in inflammatory rheumatic diseases has gained mounting interest in the last year. The paper describes special aspects of osteoporosis in rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematodes. The problems of glucocorticoid therapy are discussed intensively with regard to the recently published recommendations for glucocorticoid-induced osteoporosis. Risk factors of osteoporosis and the therapeutic implications are demonstrated intensively as well as the modifications of the recommendations.
 ...
PMID:[Specialties in therapy of osteoporosis in inflammatory joint disease]. 1522 26

Bisphosphonates are endogenous pyrophosphate analogs in which a carbon atom replaces the central atom of oxygen. They are indicated in non-neoplastic diseases including osteoporosis, corticosteroid-induced bone loss, Paget disease, and in cancer-related diseases such as neoplastic hypercalcemia, multiple myeloma and bone metastases secondary to breast and prostate cancer. There is now extensive in vitro evidence suggesting a direct antitumor effect of bisphosphonates at different levels of action. Some new in vitro and in vivo studies support the cytostatic effects of bisphosphonates on tumor cells, and the effects on the regulation of cell growth, apoptosis, angiogenesis, cell adhesion, and invasion, with particular attention to biological properties. Well designed clinical trials are necessary to investigate whether the antitumor potential of bisphosphonates may be clinically relevant. On the basis of their effects on macrophages, we may divide bisphosphonates into two distinct categories: aminobisphosphonates, which sensitize macrophages to an inflammatory stimulus inducing an acute-phase response, and non-aminobisphosphonates that can be metabolized into macrophages and that may inhibit the inflammatory response of macrophages. There is evidence of aminobisphosphonate-induced pro-inflammatory response, in particular, related to modifications of the cytokine network. Several in vivo studies have demonstrated an acute-phase reaction after the first administration of aminobisphosphonates, with a significant increase in the main pro-inflammatory cytokines. However, a peculiar aspect concerning the action of non-aminobisphosphonates seems to be an anti-inflammatory activity caused by the inhibition of the release of inflammatory mediators from activated macrophages, such as interleukin (IL)-6, tumor necrosis factor-alpha and IL-1. The inhibition of inflammatory responses is demonstrated in both in vivo and in vitro models. This activity suggests the use of non-aminobisphosphonates in several inflammatory diseases characterized by macrophage-mediated production of acute-phase cytokines, as prevention of erosions in rheumatoid arthritis, and of loosening of joint prostheses, as well as possibly in osteoarthritis, ankylosing spondylitis, myelofibrosis, and hypertrophic pulmonary osteoarthropathy.
 ...
PMID:Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. 1524 2


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>